This inventor holds 19 USPTO granted patents and 13 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Columbia University. Active years: 2003-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Cranford, NJ (US) (2003 - 2007)
- Princeton, NJ (US) (2010 - 2014)
- Perkasie, PA (US) (2014)
- Harleysville, NJ (US) (2020)
- Harleysville, PA (US) (2017 - 2021)
Company Filing History:
16 out of 2,405 
2 out of 4,770 
1 out of 2,560 
Years Active: 2003-2021
Areas of Expertise:
Title: Inventor Spotlight: Richard Berger - Pioneering Innovations in Pharmaceutical Research
Introduction:
Richard Berger, a distinguished inventor based in Princeton, NJ, has made significant contributions to the field of pharmaceutical research with his groundbreaking inventions. With a total of 19 patents to his name, Berger's work has focused on developing novel compounds to combat a range of diseases, from cancer to neurodegenerative disorders.
Latest Patents:
Berger's latest patents showcase his expertise in designing compounds with promising therapeutic potential:
1. "3-aryl-heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (HDAC6) inhibitors": Berger's invention of substituted 5-trifluoromethyl oxadiazole compounds aims to treat cellular proliferative diseases, including cancer and neurodegenerative conditions like schizophrenia and stroke.
2. "Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors": Berger's innovative pyrimidine carboxamide compounds target central nervous system disorders associated with PDE2, offering new possibilities for treating conditions such as schizophrenia and Parkinson's disease.
Career Highlights:
Throughout his career, Richard Berger has held key positions at reputable companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck & Company, Inc. His tenure at these organizations has allowed him to translate his inventive ideas into tangible solutions that have the potential to improve patient outcomes worldwide.
Collaborations:
Berger's collaborative spirit has been instrumental in bringing his inventions to fruition. Working alongside accomplished professionals such as Scott D Edmondson and Cheng Zhu, Berger has leveraged collective expertise to drive innovation and advance the boundaries of pharmaceutical research.
Conclusion:
In conclusion, Richard Berger stands out as a visionary inventor whose passion for discovery has led to the creation of impactful pharmaceutical compounds. His relentless pursuit of novel solutions for complex diseases underscores his commitment to making a difference in the field of healthcare. Berger's groundbreaking work continues to inspire and shape the future of pharmaceutical innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile